Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 0 single-dose 124I-F8IL10 PK/PD and targeting study in active rheumatoid arthritis and inflammatory bowel disease
NL-OMON39620Phase 0Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Jun 2013
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 0, open-label trial of 124I-F8IL10 in rheumatoid arthritis (RA), inflammatory bowel disease (IBD), Crohn's disease and 1 more, sponsored by Vrije University Medical Center. Started Jun 2013; status: active, not recruiting.
02
Drugs
124I-F8IL10
03
Conditions
rheumatoid arthritis (RA)inflammatory bowel disease (IBD)Crohn's diseaseautoimmune colitis
Beyond the preview
Go deeper on NL-OMON39620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39620.